OPTN - OptiNose, Inc.
Region: US
Website: optinose.com
Employees: 190
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
OptiNose, Inc. focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. Onzetra Xsail, a powder EDS device, is in Phase IIIb clinical trial.
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More
SAVA and ALNY are in the spotlight this week following a study failure and label expansion of lead drug, respectively.
Read moreOptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of 95.71% and 5.57%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Read moreOptiNose: Q4 Earnings Snapshot
YARDLEY, Pa. AP) — OptiNose Inc. OPTN) on Wednesday reported a loss of $360,000 in its fourth quarter.
Read more